This Company Is Looking For A Monkeypox Drug As City Investigates Deaths

New York City is investigating the cause of death for two people who died after contracting monkeypox. Though both of the deceased had higher fatality risk because of underlying conditions, concerns about the virus and its transmissibility have been growing.

The current number of monkeypox cases in the city stands at 3,695. Overall, there are just over 28,000 cases of monkeypox across America.

Tackling monkeypox head-on, NanoViricides Inc. NNVC is launching a monkeypox initiative. NanoViricides is a biotech company seeking treatments in the antiviral and nanomedicine space, developing a variety of drugs for diseases like COVID-19, shingles, HIV, swine flu and others. It is now hopeful as it begins developing a treatment to tackle monkeypox. 

Working Hard To Find A Cure

NanoViricides isn’t monkeying around as it begins developing a drug for the disease. It believes itself to be well positioned in the biotech field to find a treatment. It is one of the few biopharma companies to have its own current good manufacturing practice (cGMP)-compliant manufacturing facility, meaning it follows the stringent Food and Drug Administration (FDA) regulations in all its novel drug development work. 

Plus, NanoViricides has a large library of broad-spectrum antiviral nanoviricides from which it can draw to test on pox viruses. It has the resources necessary to expedite the process of finding a proper treatment. It hopes to develop a systemic treatment — one that is both oral and injectable — and may also work on a skin cream to treat the rash associated with monkeypox.

The quicker these treatments can be rolled out, the sooner they can help those infected with the disease. New York City’s health department responded to the two recent deaths with a statement: 

“We are deeply saddened by the two reported deaths and our hearts go out to the individuals' loved ones and community. Every effort will be made to prevent additional suffering from this virus through continued community engagement, information-sharing and vaccination.”

NanoViricides believes it will be able to develop a drug in response to monkeypox in relatively quick order. Meanwhile, the company’s priority remains the development of its drug candidate NV-CoV-2, for treating COVID-19.

To learn more about NanoViricides, visit its website

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Featured photo by Fusion Medical Animation on Unsplash

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechPenny StocksGeneralNanoViricidesPartner Content
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!